Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, et al.
The Lancet Oncology (2018) Vol. 19, Iss. 3, pp. 405-415
Open Access | Times Cited: 332

Showing 1-25 of 332 citing articles:

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini, Elizabeth R. Plimack, V.P. Stus, et al.
New England Journal of Medicine (2019) Vol. 380, Iss. 12, pp. 1116-1127
Open Access | Times Cited: 2805
VEGF in Signaling and Disease: Beyond Discovery and Development
Rajendra S. Apte, Daniel S. Chen, Napoleone Ferrara
Cell (2019) Vol. 176, Iss. 6, pp. 1248-1264
Open Access | Times Cited: 2039
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Ming Yi, Dechao Jiao, Hanxiao Xu, et al.
Molecular Cancer (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 665
The future of cancer immunotherapy: microenvironment-targeting combinations
Yonina R. Murciano‐Goroff, Allison Betof Warner, Jedd D. Wolchok
Cell Research (2020) Vol. 30, Iss. 6, pp. 507-519
Open Access | Times Cited: 607
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
Emmanuel S. Antonarakis, Josep M. Piulats, Marine Gross‐Goupil, et al.
Journal of Clinical Oncology (2019) Vol. 38, Iss. 5, pp. 395-405
Open Access | Times Cited: 574
Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
Jian-Ming Xu, Yun Zhang, Ru Jia, et al.
Clinical Cancer Research (2018) Vol. 25, Iss. 2, pp. 515-523
Open Access | Times Cited: 435
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Charles Pottier, Margaux Fresnais, Marie Gilon, et al.
Cancers (2020) Vol. 12, Iss. 3, pp. 731-731
Open Access | Times Cited: 433
The Intersection between Tumor Angiogenesis and Immune Suppression
Osama E. Rahma, F. Stephen Hodi
Clinical Cancer Research (2019) Vol. 25, Iss. 18, pp. 5449-5457
Closed Access | Times Cited: 391
Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy
Tianyu Tang, Xing Huang, Gang Zhang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 345
Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma
Michael B. Atkins, Nizar M. Tannir
Cancer Treatment Reviews (2018) Vol. 70, pp. 127-137
Open Access | Times Cited: 336
Immune checkpoint inhibitor–related dermatologic adverse events
Amaris Geisler, Gregory S. Phillips, Dulce M. Barrios, et al.
Journal of the American Academy of Dermatology (2020) Vol. 83, Iss. 5, pp. 1255-1268
Open Access | Times Cited: 327
Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial
Breelyn A. Wilky, Matteo Trucco, Ty K. Subhawong, et al.
The Lancet Oncology (2019) Vol. 20, Iss. 6, pp. 837-848
Closed Access | Times Cited: 316
The Mechanism of Anti–PD-L1 Antibody Efficacy against PD-L1–Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector
Wenjuan Dong, Xiaojin Wu, Shoubao Ma, et al.
Cancer Discovery (2019) Vol. 9, Iss. 10, pp. 1422-1437
Open Access | Times Cited: 251
Discovering Anti-Cancer Drugs via Computational Methods
Wenqiang Cui, Adnane Aouidate, Shouguo Wang, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 247
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
Toni K. Choueiri, James Larkin, Mototsugu Oya, et al.
The Lancet Oncology (2018) Vol. 19, Iss. 4, pp. 451-460
Closed Access | Times Cited: 243
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
Brian I. Rini, Dena Battle, Robert A. Figlin, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 231
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
Marine Gross‐Goupil, Tae‐Geon Kwon, Masatoshi Eto, et al.
Annals of Oncology (2018) Vol. 29, Iss. 12, pp. 2371-2378
Open Access | Times Cited: 223
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
Lara E. Davis, Vanessa Bolejack, Christopher W. Ryan, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 16, pp. 1424-1431
Open Access | Times Cited: 210
Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions
Aly‐Khan A. Lalani, Bradley A. McGregor, Laurence Albigès, et al.
European Urology (2018) Vol. 75, Iss. 1, pp. 100-110
Closed Access | Times Cited: 201
Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities
Stephen P. Hack, Andrew X. Zhu, Yulei Wang
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 201
Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment
Yuxiao Song, Yang Fu, Qi Xie, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 199
Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents
Daniel L. Suzman, Lorraine Pelosof, Amy S. Rosenberg, et al.
Liver International (2018) Vol. 38, Iss. 6, pp. 976-987
Open Access | Times Cited: 193
Combinations of Bevacizumab With Cancer Immunotherapy
Daniel S. Chen, Herbert I. Hurwitz
The Cancer Journal (2018) Vol. 24, Iss. 4, pp. 193-204
Closed Access | Times Cited: 181
VEGF-A drives TOX-dependent T cell exhaustion in anti–PD-1–resistant microsatellite stable colorectal cancers
Chang Gon Kim, Mi Jang, Youngun Kim, et al.
Science Immunology (2019) Vol. 4, Iss. 41
Closed Access | Times Cited: 180
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Asim Amin, Elizabeth R. Plimack, Marc S. Ernstoff, et al.
Journal for ImmunoTherapy of Cancer (2018) Vol. 6, Iss. 1
Open Access | Times Cited: 170
Page 1 - Next Page

Scroll to top